Clinical Trials Browser

Phase 1/2 × ripretinib × 90 days × Clear all

NCT05957367 2026-03-06

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Phase 1/2 Recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors